|
|
News Breaks | | | | March 5, 2013 | | 12:18 EDT |  | GILD | Gilead announces 24-week Phase 2 results for once-daily HIV regimen
Gilead Sciences announced detailed 24-week results from a Phase 2 study evaluating a once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection. A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg was found to be similar to Stribild based on the percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks of treatment. These findings were presented today in a latebreaker session at the 20th Conference on Retroviruses and Opportunistic Infections taking place in Atlanta. In Study 102, HIV-positive treatment-naïve adult patients were randomized to receive the investigational TAF-based regimen or Stribild. At 24 weeks, 87% of patients taking TAF and 90% of patients taking Stribild achieved HIV RNA less than 50 copies/mL, based on the FDA snapshot algorithm. There were no statistically significant differences in the frequency and nature of Grades 3-4 laboratory abnormalities, and the frequency and nature of adverse events were similar between the two arms. Both regimens were generally well tolerated. | |
|
News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. |
|
|
| May 21, 2013 | | 16:51 EDT | | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
 Subscribe for More Information | | | May 20, 2013 | | 07:34 EDT |  | GILD | UBS to host a conference
Subscribe for More Information | | | May 16, 2013 | | 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | | | May 15, 2013 | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | May 13, 2013 | | 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR | |
|
|
|
|
|
|
